<?xml version="1.0" encoding="UTF-8"?>
<p>Highly active antiretroviral therapy (HAART) has been effective at treating HIV infection and improving overall health and survival, but constant viral evolution continues to result in drug resistance [
 <xref rid="pone.0171124.ref001" ref-type="bibr">1</xref>]. Of the 28.3 million HIV-infected persons eligible for antiretroviral therapy (ART) in resource-limited settings (RLS), only 34% are on ART under the 2012 World Health Organization (WHO) treatment guidelines [
 <xref rid="pone.0171124.ref002" ref-type="bibr">2</xref>]. Based on the 2013 Kenya AIDS Indicator Survey, 58% of people living with HIV/AIDS (PLWHA) aged 15–64 years in Kenya were eligible for ART, but only 63% of them were found to have been initiated [
 <xref rid="pone.0171124.ref003" ref-type="bibr">3</xref>]. Primary, or transmitted drug resistance (TDR) [
 <xref rid="pone.0171124.ref004" ref-type="bibr">4</xref>] has been of a rising concern in sub-Saharan Africa (sSA) with scale-up and long-term use of antiretrovirals (ARVs) [
 <xref rid="pone.0171124.ref005" ref-type="bibr">5</xref>–
 <xref rid="pone.0171124.ref007" ref-type="bibr">7</xref>]. It accounts for 8–22% among newly HIV-infected persons in the majority of the regions of the world [
 <xref rid="pone.0171124.ref008" ref-type="bibr">8</xref>–
 <xref rid="pone.0171124.ref013" ref-type="bibr">13</xref>]. TDR may complicate the management of PLWHA [
 <xref rid="pone.0171124.ref014" ref-type="bibr">14</xref>,
 <xref rid="pone.0171124.ref015" ref-type="bibr">15</xref>], and as proposed by Hassan et al. and Nichols et al., it may reverse the benefits made from global scale-up of ART [
 <xref rid="pone.0171124.ref016" ref-type="bibr">16</xref>,
 <xref rid="pone.0171124.ref017" ref-type="bibr">17</xref>].
</p>
